Atherosclerosis and its complications remain the primary cause of death in the industrialized world and emerging economies worldwide. Dyslipidemia constitutes a significant risk factor for the development and progression of atherosclerotic lesions but may also lead to systemic disturbances - particularly metabolic dysfunction - that also influence cellular metabolism and function.